Pinocembrin as a novel anti-cancer agent: Exploring preclinical evidence along with therapeutic potential

Q: What anticancer mechanisms does pinocembrin (PB) show in preclinical studies?

PB induces intrinsic mitochondrial apoptosis, downregulating Bcl-2, upregulating Bax, promoting cytochrome C release, and activating caspases-9/3. It also inhibits PI3K/AKT and STAT3 signaling, arrests cell-cycle progression, and suppresses metastatic markers such as MMP-9 and VEGF.

Q: Why is PB oral bioavailability limited, and how can it be improved?

Oral PB in rodents undergoes rapid absorption followed by extensive first-pass glucuronidation and sulfation, producing mainly conjugates and limiting bioavailability (<10%) with a short half-life. Nanocarriers such as MPEG-PDLLA micelles and D-α-tocopheryl polyethylene glycol 1000 succinate liposomes enhance oral bioavailability and extend half-life in rodents.

Q: What safety and translational evidence supports PB development?

Toxicology reports a no-observed-adverse-effect level (NOAEL) of ≥500 mg/kg in rats without mutagenicity. Phase I trials (0.5–10 mg/kg) indicate human tolerability, though gaps remain for long-term toxicity, target validation, and prodrug development.

Sep 29, 2026

Uploaded by Aldword

Pinocembrin (PB) is a naturally occurring flavonoid with moderate lipophilicity whose preclinical anticancer effects stem from multiple mechanisms and require formulation to overcome limited bioavailability. In rodents, oral dosing faces extensive first-pass metabolism, while in vitro PB triggers intrinsic mitochondrial apoptosis by altering Bcl-2/Bax balance, releasing cytochrome c, and activating caspases-9/3; it also suppresses PI3K/AKT and STAT3 signaling, halts cell-cycle progression, and reduces metastatic markers. Corresponding in vivo xenograft/orthotopic studies show tumor growth inhibition and increased cleaved caspase-3. Nanocarriers improve pharmacokinetics and systemic exposure, while toxicology and early clinical data support tolerability. Remaining priorities include target validation, long-term safety, and prodrug development.

LanguageEnglish

CategoryHealthcare

FormatPDF

Pages21

Reading Time53 min

AccessFree to download

Abstract

Core Tip

| W | J | E | M | World Journal of
Experimental Medicine | | --- | --- | --- | --- | --- | Submit a Manuscript: [https://www.f6publishing.com](https://www.f6publishing.com) World J Exp Med 2025 December 20; 15(4): 110482 DOI: 10.5493/wjem.v15.i4.110482 ISSN 2220-315x (online) REVIEW Pinocembrin as a novel anti-cancer agent: Exploring preclinical evidence along with therapeutic potential Neelam Singla, Piyush Mittal, M Arockia Babu, Soumya V Menon, Subhashree Ray, Haider Ali, Manish Purohit, Kavita Goyal, Rakhi Mishra, Md Sadique Hussain, Arcot Rekha, Gaurav Gupta Specialty type: Medicine, research and experimental Provenance and peer review: Invited article; Externally peer reviewed. Peer-review model: Single blind Peer-review report’s classification Scientific Quality: Grade A, Grade B, Grade B Novelty: Grade A, Grade A, Grade A Creativity or Innovation: Grade B, Grade B, Grade B Scientific Significance: Grade A, Grade A, Grade A P-Reviewer: Almalki WH, Deputy Director, Saudi Arabia; Kazmi I, Additional Professor, Saudi Arabia Received: June 10, 2025 Revised: July 2, 2025 Accepted: October 9, 2025 Published online: December 20, 2025 Processing time: 195 Days and 14.9 Hours Neelam Singla, Manish Purohit, School of Pharmacy, Suresh Gyan Vihar University, Jaipur 302017, Rajasthan, India Piyush Mittal, School of Pharmacy, Sharda University, Greater Noida 201306, India M Arockia Babu, Institute of Pharmaceutical Research, GLA University, Mathura 281406, Uttar Pradesh, India Soumya V Menon, Department of Chemistry and Biochemistry, Jain (Deemed to be University), Bengaluru 560041, Karnataka, India Subhashree Ray, Department of Nephrology IMS and SUM Hospital, Siksha 'O' Anusandhan (Deemed to be University), Bhuban 751003, Odisha, India Haider Ali, Centre for Global Health Research, Saveetha Medical College, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai 602105, Tamil Nadu, India Manish Purohit, Department of Pharmacy, Govt Polytechnic Malab, Nuh 122107, Haryana, India Kavita Goyal, Department of Biotechnology, Graphic Era (Deemed to be University), Dehra Dun 248002, Uttarakhand, India Rakhi Mishra, Noida Institute of Engineering and Technology (Pharmacy Institute), Greater Noida 201306, India Md Sadique Hussain, Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehra Dun 248007, Uttarakhand, India Arcot Rekha, Dr. D.Y. Patil Medical College, Hospital and Research Centre, Pune 411018, Maharashtra, India Gaurav Gupta, Centre for Research Impact and Outcome-Chitkara College of Pharmacy, Chitkara University, Rajpura 433221, Punjab, India Gaurav Gupta, Centre of Medical and Bio-allied Health Sciences Research, Ajman University, Ajman 346, United Arab Emirates Corresponding author: Gaurav Gupta, PhD, Professor, Research Dean, Centre for Research Impact and Outcome-Chitkara College of Pharmacy, Chitkara University, Chitkara, Rajpura WJEM [https://www.wjgnet.com](https://www.wjgnet.com) 1 December 20, 2025 Volume 15 Issue 4 Singla N et al. Preclinical insights into pinocembrin’s anti-cancer potential 433221, Punjab, [India.](India. gauravpharma25@gmail.com)[ gauravpharma25@gmail.com](India. gauravpharma25@gmail.com) Abstract Pinocembrin (PB) (5,7-dihydroxy flavanone) is a naturally occurring flavonoid sourced from propolis and Pinus spp., with the formula C15H12O4 and moderate lipophilicity (log P approximately 2.1-2.5), which underlies both its bioactivity and formulation challenges. In rodents, oral administration yields rapid absorption but extensive firstpass glucuronidation and sulfation, resulting in conjugates that dominate plasma, limit bioavailability (< 10%) and confer a short half-life. In vitro, PB induces intrinsic mitochondrial apoptosis, downregulating Bcl-2, upregulating Bax, promoting cytochrome C release, and activating caspases-9/caspases-3 while inhibiting phosphoinositol-3 kinas

FAQs

What anticancer mechanisms does pinocembrin (PB) show in preclinical studies?

PB induces intrinsic mitochondrial apoptosis, downregulating Bcl-2, upregulating Bax, promoting cytochrome C release, and activating caspases-9/3. It also inhibits PI3K/AKT and STAT3 signaling, arrests cell-cycle progression, and suppresses metastatic markers such as MMP-9 and VEGF.

Why is PB oral bioavailability limited, and how can it be improved?

Oral PB in rodents undergoes rapid absorption followed by extensive first-pass glucuronidation and sulfation, producing mainly conjugates and limiting bioavailability (<10%) with a short half-life. Nanocarriers such as MPEG-PDLLA micelles and D-α-tocopheryl polyethylene glycol 1000 succinate liposomes enhance oral bioavailability and extend half-life in rodents.

What safety and translational evidence supports PB development?

Toxicology reports a no-observed-adverse-effect level (NOAEL) of ≥500 mg/kg in rats without mutagenicity. Phase I trials (0.5–10 mg/kg) indicate human tolerability, though gaps remain for long-term toxicity, target validation, and prodrug development.

Sep 29, 2026

Uploaded by Aldword